TOSHIBA
27.8.2020 07:02:11 CEST | Business Wire | Press release
Toshiba Electronic Devices & Storage Corporation (“Toshiba”) has launched three photorelays: “TLP3407SRA ,” “TLP3475SRHA ” and “TLP3412SRHA ,” that are the industry-smallest[1] voltage driven photorelays with an extended operating temperature rating of 125°C.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200826005815/en/
Raising the maximum operating temperature rating from 110°C to 125°C allows the photorelays to be mounted in high temperature areas, and makes it easier to secure required temperature design margins for equipment. The S-VSON4T package has the industry-smallest[1] mounting area of 2.9mm² .This will contribute to reducing PCB size or to increasing the number of photorelays in an existing layout in applications such as semiconductor testers, probe cards and other devices.
Applications
- Semiconductor testers (memory, SoC and LSI, etc.)
- Probe cards
- Burn-in equipment
- Measuring instruments (oscilloscope, data logger, etc.)
Features
- S-VSON4T, the industry’s first[1] packaging with a minimal mounting area and maximum operating temperature of 125°C: Mounting area 2.9mm2 (typ.)
- Low input power consumption drive: 3.3mW[2] (max) @VIN =3.3V (TLP3407SRA)
Main Specifications
(＠Ta =25℃) |
||||
Part number |
||||
Package |
Name |
S-VSON4T |
||
Size typ. (mm) |
2.0×1.45 |
|||
Height typ.(mm) |
1.3 |
|||
Recommended
|
Applied input forward voltage VIN typ. (V) |
3.3 |
3.3 |
3.3 |
Built-in resistance typ. (Ω) |
4000 |
600 |
600 |
|
Absolute maximum ratings |
OFF-state output terminal voltage VOFF (V) |
60 |
60 |
60 |
ON-state current ION (A) |
1 |
0.4 |
0.4 |
|
ON-state current (pulsed) IONP (A) |
3 |
1.2 |
1.2 |
|
Operating temperature Topr (℃) |
-40 to 125 |
|||
Coupled
|
Limited LED current ILIM(LED) max (mA) (@VIN ) |
1
|
- |
- |
Trigger LED current IFT max (mA) |
0.2 |
2 |
2 |
|
Operating voltage VFON max (V) |
3 |
3 |
3 |
|
ON-state resistance RON max (Ω) |
0.3 |
1.5 |
1.5 |
|
Electrical characteristics |
Output capacitance COFF typ. (pF) |
80 |
12 |
20 (max) |
OFF-state current IOFF max (nA) (@VOFF ) |
1 (@50V) |
1 (@50V) |
1 (@50V) |
|
Switching characteristics |
Turn-on time tON max (ms) |
20 |
0.5 |
0.5 |
Turn-off time tOFF max (ms) |
1 |
0.2 |
0.2 |
|
Isolation characteristic |
Isolation voltage BVS min (Vrms) |
500 |
500 |
500 |
Sample Check & Availability |
||||
Notes:
[1] For photorelays where maximum operating temperature rating is 125°C, according to a survey by Toshiba (as of August 25, 2020).
[2] Applied input forward voltage × maximum limited LED current=3.3V×1mA
Follow the link below for more on the new photocouplers.
TLP3407SRA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3407SRA
TLP3475SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3475SRHA
TLP3412SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3412SRHA
Follow the link below for more on Toshiba’s photorelay lineup.
https://toshiba.semicon-storage.com/ap-en/semiconductor/product/optoelectronics/photorelay-mosfet-output.html
To check availability of the new products at online distributors, visit:
TLP3407SRA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3407SRA.html
TLP3475SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3475SRHA.html
TLP3412SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3412SRHA.html
Customer Inquiries:
Optoelectronic Device Sales & Marketing Dept.
Tel: +81-3-3457-3431
https://toshiba.semicon-storage.com/ap-en/contact.html
* Company names, product names, and service names may be trademarks of their respective companies.
* Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.
About Toshiba Electronic Devices & Storage Corporation
Toshiba Electronic Devices & Storage Corporation combines the vigor of a new company with the wisdom of experience. Since becoming an independent company in July 2017, the company has taken its place among the leading general devices companies, and offers its customers and business partners outstanding solutions in discrete semiconductors, system LSIs and HDD.
Its 24,000 employees around the world share a determination to maximize the value of its products, and emphasize close collaboration with customers to promote co-creation of value and new markets. The company looks forward to building on annual sales now surpassing 750-billion yen (US$6.8 billion) and to contributing to a better future for people everywhere.
Find out more about Toshiba Electronic Devices & Storage Corporation at https://toshiba.semicon-storage.com/ap-en/top.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom